Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13995823 | 0.84 | SMN1; SMN2 (0.63) | SMN1; SMN2RAB9ANPC1HPGDMAPT | |
| SCHEMBL15948524 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL30211804 | 0.73 | MEN1 (0.43) | SMN1; SMN2RAB9ANPC1HPGDMAPT | |
| SCHEMBL1540171 | 0.73 | RAB9A (0.50) | SMN1; SMN2RAB9ANPC1HPGDMAPT | |
| SCHEMBL27415713 | 0.72 | SMN1; SMN2 (0.47) | SMN1; SMN2RAB9ANPC1HPGDMAPT | |
| SCHEMBL10969470 | 0.72 | SMN1; SMN2 (0.54) | SMN1; SMN2RAB9ANPC1HPGDMAPT | |
| SCHEMBL11116642 | 0.72 | — | — | |
| SCHEMBL11534359 | 0.72 | SMN1; SMN2 (0.49) | SMN1; SMN2RAB9ANPC1HPGDMAPT | |
| SCHEMBL11534361 | 0.72 | SMN1; SMN2 (0.49) | SMN1; SMN2RAB9ANPC1HPGDMAPT | |
| SCHEMBL15331825 | 0.71 | SMN1; SMN2 (0.49) | SMN1; SMN2RAB9ANPC1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973047-B2 | Beta-Secretase modulators and methods of use | AMGEN INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | SMN1; SMN2 1679/4885RAB9A 1585/4885NPC1 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.